The purpose of this case-control study is to assess the contributions of the glutathione S-transferase (GST; genes and the cytochrome P-450 (CUP) genes to the genetic susceptibility of brain tumors and to study the effect of these genetic polymorphisms on the treatment outcome and toxicity of brain tumors. Studies to date suggest a moderate to large effect for GSTTl in selected tumor subtypes. We are targeting obtaining data on approximately 1000 cases and controls, with an adequate number of glioblastomas (n=430), astrocytomas (n=300), oligodendrogliomas (n=100) and meningiomas (n=l50) to evaluate this hypothesis with reasonable power for relative risks previously reported in the literature for GSTTl. All study subjects will be asked to complete a computer assisted self-administered questionnaire and to provide blood and/or buccal cell samples for DNA analysis. An estimated 770 recently diagnosed cases (within three months of initial diagnosis) will be recruited by research nurses from Duke University Cancer Center and 220 cases in Evanston Hospital in Evanston, IL over a four year period. An equal number of friend controls will be identified by asking each case for the name of five friends of approximately the same age (+1- 5 years), gender and race. These controls will be recruited by the research nurse and given the option of completing the protocol during an appointment at the respective clinic or using a distance based protocol. Medical records will be reviewed to obtain the clinical and treatment information for the survival and toxicity portions of the study. Linkage with the National Death Index in Year four will be completed to obtain vital statistics information and provide up to three years of follow-up time in which to assess outcomes. Study coordination and survey data management will be completed at the University of Illinois at Chicago; molecular analysis will be conducted in the laboratory of Dr. Ali-Osman at M.D. Anderson Cancer Center. The Duke Cancer Center will facilitate the neuropathology review, provide some local data collection and management support and store the remaining specimens in their central repository. Data analysis files will be compiled at UIC and statistical analysis will be completed using conditional logistic regression models as appropriate to each specific aim.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA096890-01
Application #
6685596
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-30
Project End
2004-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Bota, Daniela A; Alexandru, Daniela; Keir, Stephen T et al. (2013) Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. J Neurosurg 119:1415-23
Lou, Emil; Sumrall, Ashley L; Turner, Scott et al. (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109:63-70
Reardon, David A; Vredenburgh, James J; Desjardins, Annick et al. (2012) Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol 108:499-506
Reardon, David A; Vredenburgh, James J; Desjardins, Annick et al. (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101:57-66
Reardon, David A; Desjardins, Annick; Peters, Katherine et al. (2011) Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103:371-9
McCarthy, Bridget J; Rankin, Kristin M; Aldape, Ken et al. (2011) Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol 13:242-50
Vredenburgh, James J; Desjardins, Annick; Reardon, David A et al. (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119-24
Reardon, David A; Desjardins, Annick; Vredenburgh, James J et al. (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219-30
Choi, Bryan D; Archer, Gary E; Mitchell, Duane A et al. (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19:713-23
Duncan, Christopher G; Leary, Rebecca J; Lin, Jimmy Cheng-Ho et al. (2009) Identification of microbial DNA in human cancer. BMC Med Genomics 2:22

Showing the most recent 10 out of 28 publications